Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alumis Inc. - Common Stock (NQ:ALMS)

26.19 -1.91 (-6.80%)
Streaming Delayed Price Updated: 3:50 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alumis Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition. 
Via The Motley Fool
News headline image
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million ↗
Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz. 
Via Stocktwits
Topics ETFs Government Stocks
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
Dow Clears 49,000 as AI’s “Data Deluge” Ignites a Memory-Stock Melt-Up ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential ↗
The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data. 
Via Stocktwits
News headline image
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. 
Via The Motley Fool
Topics Stocks
News headline image
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
Via AB Newswire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Why Is ALMS Stock Rising Today? ↗
Alumis announced positive results from both of its Phase 3 clinical trials of envudeucitinib. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
From Alumis Inc.
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗
Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
A full exit during a volatile stretch raises a sharper question than timing alone. 
Via The Motley Fool
News headline image
What's going on in today's session ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alumis Misses Q2 Revenue as Costs Jump ↗
Via The Motley Fool
News headline image
Top movers in Tuesday's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today 
From ACELYRIN, INC.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.